Nicolas Salavin is the Chief Technology Officer, with the responsibility to implement a technological roadmap and lead new and long-term growth opportunities for ABL.

Over the past 20 years, Nicolas has held positions within Sanofi and Total, in process development, GMP pilot operations, commercial manufacturing assistance, technology transfer, engineering, strategic portfolio management and corporate transformation programs. Nicolas has acquired significant CMC experience from preclinical to commercial, on several modalities including Recombinant Proteins, Monoclonal Antibodies, Viral Vaccines, and mRNA.

Nicolas holds a Master’s degree in Biology and Process Engineering from AgroParisTech.